Lenercept

来那西普

Report date: 2024/06/27 15:39:29

Base Information

Drug NameLenercept
Drug Alias NameTenefuseRO-452081NFR55-IgG1TNFR55-Ig1p55TNFR-Ig
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionImmunosuppressantsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidShock, Septic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidShock, Septic

Other Information

ATC CodeN/A
Related LinksN/A